Spots Global Cancer Trial Database for fallopian tube
Every month we try and update this database with for fallopian tube cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | NCT02485990 | Primary Periton... | Tremelimumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | NCT01519869 | Primary Periton... Ovarian Carcino... Fallopian Tube ... | neoadjuvant che... | 18 Years - | University of Kentucky | |
| A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer | NCT03245892 | High Grade Sero... Fallopian Tube Primary Periton... | Carboplatin and... Nivolumab Cytoreductive s... Ipilimumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab | NCT01223235 | Fallopian Tubes... Ovarian Cancer Peritoneal Canc... | bevacizumab and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | NCT06173037 | Primary Periton... Fallopian Tube Epithelial Ovar... | RC88 | 18 Years - | RemeGen Co., Ltd. | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| Fermented Wheat Germ Extract in Women With Ovarian Cancer | NCT02411565 | Ovarian Cancer | Fermented Wheat... Placebo Standard of Car... Quality of Life... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | NCT01219777 | Ovarian Cancer Primary Periton... Fallopian Tube ... | carboplatin Bevacizumab Paclitaxel | 18 Years - 90 Years | Ohio State University Comprehensive Cancer Center | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | NCT01220154 | Ovarian Cancer Fallopian Tube ... Primary Periton... No Prior Chemot... | Paclitaxel Carboplatin Bevacizumab | 18 Years - 90 Years | Ohio State University Comprehensive Cancer Center | |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | NCT02354586 | Ovarian Neoplas... Ovarian Cancer | Niraparib | 18 Years - | Tesaro, Inc. | |
| Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer | NCT01591772 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | Neuroimaging & ... Neuroimaging & ... | 21 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema | NCT00944944 | Ovarian Cancer Uterine Cancer Vaginal Cancer Lymphedema | limb volume mea... GCLQ lymphedema... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | NCT00421889 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Bladder Cancer | belinostat Paclitaxel Carboplatin | 18 Years - | Valerio Therapeutics | |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive | NCT01262040 | Endometrial Can... Fallopian Tube ... Ovarian Cancer Peritoneal Canc... Gastrointestina... Pancreatic Carc... Lung Cancer Esophageal Carc... | Narrow Band Ima... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | NCT00501644 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Carboplatin GM-CSF (Sargram... Interferon Gamm... | - | M.D. Anderson Cancer Center | |
| Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab | NCT01223235 | Fallopian Tubes... Ovarian Cancer Peritoneal Canc... | bevacizumab and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema | NCT00944944 | Ovarian Cancer Uterine Cancer Vaginal Cancer Lymphedema | limb volume mea... GCLQ lymphedema... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer | NCT01826227 | Ovarian Cancer Fallopian Tube Primary Periton... | Positron Emissi... 18F-Fluoro-2-de... Cytoreductive s... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study | NCT01271959 | Solid Organ Tum... | 18 Years - | Precision Therapeutics | ||
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | NCT00421889 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Bladder Cancer | belinostat Paclitaxel Carboplatin | 18 Years - | Valerio Therapeutics | |
| A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer | NCT03245892 | High Grade Sero... Fallopian Tube Primary Periton... | Carboplatin and... Nivolumab Cytoreductive s... Ipilimumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | NCT00501644 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Carboplatin GM-CSF (Sargram... Interferon Gamm... | - | M.D. Anderson Cancer Center | |
| Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive | NCT01262040 | Endometrial Can... Fallopian Tube ... Ovarian Cancer Peritoneal Canc... Gastrointestina... Pancreatic Carc... Lung Cancer Esophageal Carc... | Narrow Band Ima... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | NCT02485990 | Primary Periton... | Tremelimumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | NCT03326193 | Ovarian Neoplas... | Niraparib Bevacizumab | 18 Years - | Tesaro, Inc. | |
| Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | NCT02718417 | Ovarian Cancer | carboplatin paclitaxel Avelumab Avelumab | 18 Years - | Pfizer | |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | NCT02354586 | Ovarian Neoplas... Ovarian Cancer | Niraparib | 18 Years - | Tesaro, Inc. | |
| RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | NCT06173037 | Primary Periton... Fallopian Tube Epithelial Ovar... | RC88 | 18 Years - | RemeGen Co., Ltd. | |
| ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | NCT03287271 | Ovarian Cancer | VS-6063 Paclitaxel Carboplatin | 18 Years - | University of California, San Diego | |
| Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | NCT01974765 | Advanced Epithe... Recurrent Epith... Fallopian Tube Primary Periton... | Enzalutamide | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
